Etoposide and Cisplatin in Treating Young Patients With Previously Untreated High-Risk Neuroblastoma Undergoing High-Dose Chemotherapy Stem Cell Transplant and Isotretinoin

  • STATUS
    Recruiting
  • participants needed
    30
  • sponsor
    Baylor College of Medicine
Updated on 7 November 2020
stem cell transplantation
cyclophosphamide
filgrastim
melphalan
isotretinoin
x-rays
etoposide
doxorubicin
combination chemotherapy
carboplatin
tumor cells
conventional surgery
high-risk neuroblastoma

Summary

RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) and giving them in different doses may kill more tumor cells. Radiation therapy uses high-energy x-rays to kill tumor cells. Peripheral blood stem cell transplant using stem cells from the patient may be able to replace immune cells that were destroyed by chemotherapy and radiation therapy used to kill tumor cells. PURPOSE: This phase II trial is studying the side effects and how well giving etoposide together with cisplatin works in treating young patients with previously untreated high-risk neuroblastoma undergoing high-dose chemotherapy, stem cell transplant, and isotretinoin.

Description

OBJECTIVES: Primary - Estimate the response rate associated with two courses of cisplatin and protracted oral etoposide when administered as up-front window therapy to pediatric patients with previously untreated high-risk neuroblastoma undergoing high-dose chemotherapy and stem cell rescue followed by maintenance therapy comprising isotretinoin. - Describe the toxicities associated with cisplatin and protracted oral etoposide when administered as up-front window therapy to these patients. Secondary - Evaluate the induction response rates, patterns of treatment failure, event-free survival , and overall survival of children with high-risk neuroblastoma treated with this regimen. - Evaluate the feasibility and toxicity of resection of primary tumors after two courses of induction chemotherapy. - Describe the antiangiogenic effects of cisplatin and protracted oral etoposide in these patients. - Estimate the change in neuropsychological assessment battery in children > 2 years old at diagnosis and correlate these changes with toxicities of therapy. - Provide a consistent treatment strategy as a platform for the study of biologic features of the tumor and patient. OUTLINE: This is a multicenter study. - Induction therapy: Courses of induction therapy are 21 days in duration. - Courses 1, 2, and 4: Patients receive cisplatin IV over 6 hours on days 1-5 and oral protracted etoposide* once daily on days 1-14. Patients with responding disease after course 2 receive cisplatin and oral protracted etoposide as above during course 4. Patients with stable disease, residual disease, or progressive disease after course 2 receive cisplatin IV over 6 hours and etoposide IV over 1 hour on days 2-4 during course 4. - Courses 3 and 5: Patients receive cyclophosphamide IV over 6 hours and doxorubicin hydrochloride IV over 15 minutes on days 1-2. Patients also receive filgrastim (G-CSF) subcutaneously (SC) once daily beginning on day 3 and continuing until blood counts recover. Patients undergo peripheral blood stem cell collection after course 3. NOTE: *Patients who are ineligible to participate or choose not to participate in the phase II window (e.g., treatment with oral protracted etoposide) receive cisplatin as above and etoposide IV over 1 hour on days 2-4 during courses 1, 2, and 4. - Consolidation therapy: - Radiotherapy: Beginning within 6 weeks after starting the final course of induction therapy, patients undergo radiotherapy for local control of neuroblastoma (approximately 2,400 cGy in 12 doses). Patients then proceed to high-dose chemotherapy and stem cell rescue (HDT/SCR). - HDT/SCR: Beginning within 1-2 weeks after completion of radiotherapy, patients receive carboplatin IV continuously and etoposide IV continuously on days -7 to -4 and melphalan IV on days -7 to -5. Patients undergo SCR with autologous peripheral blood progenitor cells on day 0. Patients also receive G-CSF SC once daily beginning on day 5 and continuing until blood counts recover. - Maintenance therapy: Beginning on day 90 after HDT/SCR, patients with responding disease receive oral isotretinoin twice daily on days 1-14. Treatment repeats every 28 days for 6 courses. - Surgery: Patients undergo delayed surgical resection of the primary tumor after course 2 of induction therapy if the tumor is considered resectable. If the tumor is not considered resectable after course 2 of induction therapy, a reevaluation of the primary tumor should occur after course 3 and again after course 5 of induction therapy, if needed. Blood and tissue samples are collected for correlative studies. Tissue samples are analyzed by immunohistochemistry, microvessel density assessment, and molecular techniques for angiogenic factors (VEGF and MMP-9). Blood samples are analyzed for the presence of circulating endothelial cells and angiogenesis factors. Patients receiving oral protracted etoposide who are ≥ 2 years of age at diagnosis and proceed to consolidation therapy undergo neuropsychological assessment after course 2 of induction therapy, annually until 8 years of age, and then clinician choice of annually or every other year (based on test results). After completion of study treatment, patients are followed every 3 months for 1 year, every 4 months for 1 year, every 6 months for 1 year, and then annually thereafter.

Details
Condition Neuroblastoma
Treatment conventional surgery, radiation therapy, cyclophosphamide, laboratory biomarker analysis, cisplatin, filgrastim, doxorubicin hydrochloride, etoposide, immunohistochemistry staining method, melphalan, peripheral blood stem cell transplantation, carboplatin, isotretinoin
Clinical Study IdentifierNCT00600132
SponsorBaylor College of Medicine
Last Modified on7 November 2020

Eligibility

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar
Name

Primary Contact

site
Name

Phone Email

0/250
Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note